Cancer diagnosis & prognosis最新文献

Comparison of the Preoperative MRI Evaluation of Glandular Tissue in Subcutaneous Mastectomy and its Influence on the Implant Volume. 皮下乳房切除术中腺体组织的术前 MRI 评估及其对植入物体积影响的比较

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10369

Hanna Fritsch, Rebecca Tumeltshammer, Jens Hachenberg, Mathias Warm, Barbara Krug, Wolfram Malter, Christian Eichler

{"title":"Comparison of the Preoperative MRI Evaluation of Glandular Tissue in Subcutaneous Mastectomy and its Influence on the Implant Volume.","authors":"Hanna Fritsch, Rebecca Tumeltshammer, Jens Hachenberg, Mathias Warm, Barbara Krug, Wolfram Malter, Christian Eichler","doi":"10.21873/cdp.10369","DOIUrl":"https://doi.org/10.21873/cdp.10369","url":null,"abstract":"Background/aim: This study examined the influence of preoperative MRI on the choice of implant volume in patients undergoing subcutaneous mastectomy with immediate breast reconstruction. It was postulated that preoperative MRI scans can adequately estimate glandular tissue, which in turn correlates with implant size.Patients and methods: Preoperative and postoperative MRI scans were used in oncological and prophylactical subcutaneous mastectomy scenarios in 67 cases at the Department of Gynaecology, Breast Cancer Center, University of Cologne, Germany. The preoperative MRI was used to estimate the resected tissue and the postoperative MRI was used to scan for residual glandular tissue. In addition, a correlation found by Malter et al. in 2021 was evaluated with the available data.Results: Preoperative MRIs result in an adequate estimation of resected tissue. This in turn correlates with implant volume. The correlation by Malter et al. also holds when estimating implant volume. The likelihood of residual gland was low if the preoperatively estimate volume was removed.Conclusion: Our results indicate that the use of preoperative and postoperative MRI scans for subcutaneous mastectomies is advantageous. We suggest a routine estimation of glandular tissue, especially for small breasts.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Perioperative Physical Activity on Skeletal Muscle Loss 6 Months After Esophageal Cancer Surgery. 食管癌术后 6 个月围手术期体育锻炼对骨骼肌损失的影响

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10379

Junko Honke, Yoshihiro Hiramatsu, Keiko Mori, Sanshiro Kawata, Yoshifumi Morita, Hirotoshi Kikuchi, Hiroya Takeuchi

{"title":"Effect of Perioperative Physical Activity on Skeletal Muscle Loss 6 Months After Esophageal Cancer Surgery.","authors":"Junko Honke, Yoshihiro Hiramatsu, Keiko Mori, Sanshiro Kawata, Yoshifumi Morita, Hirotoshi Kikuchi, Hiroya Takeuchi","doi":"10.21873/cdp.10379","DOIUrl":"https://doi.org/10.21873/cdp.10379","url":null,"abstract":"Background/aim: Sarcopenia contributes to a poor prognosis in patients with esophageal cancer; thus, any clinical support that prevents loss of skeletal muscle mass preoperatively and postoperatively should be actively investigated. This study aimed to evaluate physical activity during the perioperative period and its impact on postoperative skeletal muscle mass.Patients and methods: Sixty-two patients who underwent esophagostomy at the Hamamatsu University School of Medicine between 2019 and 2023 were evaluated. The physical activity (measured by the step count) of patients scheduled for esophagectomy was assessed preoperatively using a fitness tracker. The percentage change in skeletal muscle mass index (SMI) was calculated preoperatively and 6 months postoperatively. Factors associated with decreased SMI 6 months after esophagectomy were analyzed using multivariate analysis.Results: The median decrease in SMI was -6.2%. Multivariate analysis revealed that factors associated with the reduction of SMI were age >69 years [odds ratio (OR)=7.21, 95% confidence interval (CI)=1.36-38.19, p=0.020], preoperative step count <7,800 steps/day (OR=5.17, 95% CI=1.38-19.33, p=0.015), and postoperative step count <2,400 steps/day (OR=3.55, 95% CI=1.01-12.45, p=0.048).Conclusion: A low perioperative step count and older age were significant risk factors for skeletal muscle loss in patients with esophageal cancer undergoing surgery. For patients with a low number of steps in the perioperative period or for older patients, interventions to increase the number of steps may prevent skeletal muscle loss.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Microsurgery and Fluorescent-reporter Genes in Establishing Mouse Models for Real-Time Imaging of Metastatic Cancer-Cell Trafficking and Colony Formation: A Revolutionary and Disruptive Technology for Metastasis Research. 显微手术和荧光报告基因在建立转移癌细胞迁移和集落形成实时成像小鼠模型中的作用：转移研究的革命性和颠覆性技术。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10362

Sei Morinaga, Norio Yamamoto, Kensuke Yamauchi, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman

{"title":"The Role of Microsurgery and Fluorescent-reporter Genes in Establishing Mouse Models for Real-Time Imaging of Metastatic Cancer-Cell Trafficking and Colony Formation: A Revolutionary and Disruptive Technology for Metastasis Research.","authors":"Sei Morinaga, Norio Yamamoto, Kensuke Yamauchi, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman","doi":"10.21873/cdp.10362","DOIUrl":"https://doi.org/10.21873/cdp.10362","url":null,"abstract":"The field of experimental microsurgery was pioneered by the great microsurgeon Sun Lee, who developed the foundation of transplant surgery in the clinic. Dr Lee also played a seminal role in introducing microsurgery to establish mouse models of cancer. In 1990, at the age of 70, Dr Lee demonstrated microsurgery techniques to the mouse-model team at AntiCancer Inc., leading to the development of the surgical orthotopic implant (SOI) technique and the first orthotopic mouse models of cancer that metastasized in a pattern similar to clinical cancer. At the beginning of the present century, one of us (NY) from Kanazawa University School of Medicine became a visiting scientist at AntiCancer to learn SOI and develop mouse models of cancer using cancer cells expressing fluorescent reporter genes, such as green fluorescent protein (GFP) and red fluorescent protein (RFP), in order to image metastatic cancer cells trafficking in real time. Since then, a total of eight young surgeons from Kanazawa University have been visiting researchers at AntiCancer, developing SOI mouse models of cancer to visualize cancer cells in vivo, tracking all stages of metastasis in real time. The present perspective review summarizes this seminal work, which has revolutionized the field of metastasis research.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disproportionality Analysis of Osimertinib-related Adverse Events in Elderly Patients Using the Japanese Pharmacovigilance Database. 利用日本药物警戒数据库对老年患者中奥希替尼相关不良事件进行比例分析

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10374

Takashi Omoto, Junichi Asaka, Kenzo Kudo

{"title":"Disproportionality Analysis of Osimertinib-related Adverse Events in Elderly Patients Using the Japanese Pharmacovigilance Database.","authors":"Takashi Omoto, Junichi Asaka, Kenzo Kudo","doi":"10.21873/cdp.10374","DOIUrl":"https://doi.org/10.21873/cdp.10374","url":null,"abstract":"Background/aim: Osimertinib is a well-tolerated first- or second-line treatment option for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer. However, the safety of osimertinib in elderly patients requires further investigation. Herein, we identified safety signals for various osimertinib-related adverse events (AEs) in elderly patients by disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database.Patients and methods: Data from the JADER database from April 2004 to March 2023 were obtained from the Pharmaceuticals and Medical Devices Agency website. Safety signal detection for osimertinib-related AEs in elderly patients (≥70 years old) was determined using the relative elderly reporting odds ratio (ROR). For osimertinib-related AEs, we extracted 92 preferred terms (PTs) and nine standardized MedDRA queries (SMQs).Results: Safety signals in elderly patients were detected for \"Cardiomyopathy (PT)\" and \"Cardiomyopathy (SMQ)\". The symptoms most frequently associated with \"Cardiomyopathy (SMQ)\" included \"Ejection fraction decreased (PT)\", \"Cardiomyopathy (PT)\", and \"Stress cardiomyopathy (PT)\". Notably, 53.7% of these outcomes were \"Recovery\" or \"Remission\". The median time to the onset of \"Cardiomyopathy (SMQ)\" in elderly patients was 85 days (range=2-537 days).Conclusion: We demonstrated that patients ≥70 years potentially have increased osimertinib-related cardiomyopathy compared with patients <70 years. In the future, it is necessary to conduct research focusing on cardiomyopathy in elderly patients.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions. 透明细胞肾细胞癌的免疫治疗创新：当前策略与未来方向。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10363

Stefania Chipuc, Haineala Bogdan, Dragos Serban, Dumitru Cristinel Badiu, Anca Zgura, Rodica Anghel

{"title":"Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.","authors":"Stefania Chipuc, Haineala Bogdan, Dragos Serban, Dumitru Cristinel Badiu, Anca Zgura, Rodica Anghel","doi":"10.21873/cdp.10363","DOIUrl":"https://doi.org/10.21873/cdp.10363","url":null,"abstract":"Approximatively 80% of kidney cancers globally are clear cell kidney cancers (ccRCCs), with 80% of these malignancies featuring an inactivating mutation of the Von Hippel-Lindau gene. This genetic alteration leads to the stabilization of hypoxia inducible factors 1 and 2 alpha (HIF 1 and 2α), resulting in the over-expression of target genes such as vascular endothelial growth factor (VEGF), which is crucial for angiogenesis. As a result, ccRCCs are highly vascularized and serve as models for anti-angiogenic treatments (AAT). Current AAT therapies comprise antibodies targeting VEGFs, tyrosine kinase inhibitors (TKi) (Sunitinib) that target neo-angiogenesis receptors, and competitive inhibitor receptors (Aflibercept) that trap VEGFA and PlGF. The over-expression of VEGF and related members such as VEGFC significantly influences angiogenesis, lymph-angiogenesis, and immune tolerance. This has resulted in the approval of various immune checkpoint inhibitors (known as anti-PD-1, anti-PD-L1, and anti-CTLA-4) as viable treatment options for kidney cancer. Despite these advances, ccRCC remains challenging to treat adequately. Thus, future research is imperative to better understand the biology and pathophysiology of RCC, the tumor microenvironment, and mechanisms of resistance, with the aim of developing new therapies.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer. 骨形态发生蛋白 8B (BMP8B) 在胃癌疾病进展中的推定双重作用

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10365

Zhiwei Sun, Shuo Cai, Xiangyi Liu, Wen G Jiang, Lin Ye

{"title":"Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer.","authors":"Zhiwei Sun, Shuo Cai, Xiangyi Liu, Wen G Jiang, Lin Ye","doi":"10.21873/cdp.10365","DOIUrl":"https://doi.org/10.21873/cdp.10365","url":null,"abstract":"Background/aim: Increased expression of bone morphogenetic protein 8B (BMP8B) in bone marrow and primary tumors of patients with gastric cancer (GC) is associated with disease progression and poor prognosis. However, a reduced expression has also been seen in GCs due to histone acetylation. This study aimed to evaluate BMP8B transcript levels in a large GC cohort and its impact on cellular functions.Materials and methods: BMP8B transcripts were determined in 319 gastric tumors and compared with 182 adjacent normal tissues using real time PCR, with a further analysis conducted in the TCGA database. Kaplan-Meier plotter analysis was performed to evaluate the correlation between BMP8B and prognosis of the disease. BMP8B knockdown model was employed to determine the effect of BMP8B on the function of GC cells (HGC27).Results: BMP8B mRNA levels were significantly up-regulated in the GC tissues compared with adjacent normal tissues in both TCGA database and our own database from Beijing Cancer Hospital, and high BMP8B expression was associated with poor prognosis. BMP8B is most likely to be involved in the differentiation of GC. Poorly differentiated GC samples presented a significantly reduced BMP8B expression in relation to well-differentiated and moderately differentiated GC. BMP8B knockdown inhibited proliferation of GC cells, while promoted invasion and migration of cancer cells.Conclusion: BMP8B was reduced in GCs, whereas higher BMP8B expression was associated with poor prognosis. BMP8B knockdown inhibited proliferation of GC cells, and promoted invasion and migration. Our results suggest that BMP8B plays dual roles in GC.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor. 阿特珠单抗联合贝伐单抗治疗无法切除的肝细胞癌：西班牙单个三级中心的实际经验以及作为生存预后因素的 ALBI 评分。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10373

María Pilar Ballester, Carlos Abril, Víctor Merino, Manuel Alós, Gloria Segarra, Joan Tosca, Cristina Montón, Nuria Casasus, Paloma Lluch

{"title":"Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor.","authors":"María Pilar Ballester, Carlos Abril, Víctor Merino, Manuel Alós, Gloria Segarra, Joan Tosca, Cristina Montón, Nuria Casasus, Paloma Lluch","doi":"10.21873/cdp.10373","DOIUrl":"https://doi.org/10.21873/cdp.10373","url":null,"abstract":"Background/aim: Atezolizumab/bevacizumab (atez/bev) has been established as first-line systemic treatment for hepatocellular carcinoma (HCC). However, concerns regarding safety and efficacy have been raised, and no biomarkers to predict response have yet been identified. We aimed to evaluate the real-life experience of atez/bev in a Spanish tertiary hospital and identify factors associated with overall survival (OS).Patients and methods: A prospective study of consecutive patients with HCC treated with atez/bev was conducted from December 2020 to December 2022. Efficacy was assessed through OS and progression-free survival (PFS), whereas safety was evaluated based on adverse events (AE). Twenty-three patients were included; 91% were males with a mean of 70 years. Thirteen patients were classified as having BCLC-C.Results: The median treatment duration was 126 days (range=567). Median OS was 381 days (95%CI=205-557) with a cumulative probability of death of 13%, 30%, and 49% at 3, 6 and 12-month follow-up, respectively. The only factor associated with OS was the ALBI score (HR=5.03; 95%CI=1.3-19.1), which showed an AUROC of 0.906 (95%CI=0.78-1.00) for the risk of death at 18 months follow up. Median PFS was 141 days (95%CI=110-172). Twenty (86.9%) patients experienced AE, which in nine (39.1%) cases led to the definitive discontinuation of the treatment, four of them (17.4%) due to an AE grade 5.Conclusion: The initial experience with atez/bev at our center demonstrated poorer outcomes compared to the original trial (IMbrave150). A careful assessment of the ALBI score may serve as a crucial factor in the selection of systemic treatment for patients with HCC.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic Impacts of Aldehyde Dehydrogenase 2 Genetic Variants on Hepatocellular Carcinoma Susceptibility. 醛脱氢酶 2 基因变异对肝细胞癌易感性的诊断影响

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10366

Yu-Ting Chin, Ming-Hsien Wu, Hou-Yu Shih, Chia-Wen Tsai, Jen-Sheng Pei, Tao-Wei Ke, Yun-Chi Wang, Yi-Chih Hung, Jaw-Chyun Chen, DA-Tian Bau, Wen-Shin Chang

{"title":"Diagnostic Impacts of Aldehyde Dehydrogenase 2 Genetic Variants on Hepatocellular Carcinoma Susceptibility.","authors":"Yu-Ting Chin, Ming-Hsien Wu, Hou-Yu Shih, Chia-Wen Tsai, Jen-Sheng Pei, Tao-Wei Ke, Yun-Chi Wang, Yi-Chih Hung, Jaw-Chyun Chen, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/cdp.10366","DOIUrl":"https://doi.org/10.21873/cdp.10366","url":null,"abstract":"Background/aim: The role of alcohol consumption and aldehyde dehydrogenase 2 (ALDH2) genotype in hepatocellular carcinoma (HCC) development remains uncertain.Materials and methods: We conducted genotyping of the ALDH2 rs671 single nucleotide polymorphism in 298 patients with HCC and 889 non-cancerous healthy controls. We assessed associations stratified by sex and alcohol consumption status.Results: Distribution of ALDH2 rs671 variant genotypes differed significantly between HCC patients and controls (ptrend=0.0311). Logistic regression analyses indicated that compared to the wild-type GG genotype, the heterozygous variant AG genotype and homozygous variant AA genotype conferred 1.22- and 1.77-fold increases in HCC risk (p=0.1794 and 0.0150, respectively). Allelic frequency analysis showed that the A allele was associated with a 1.29-fold increased HCC risk (p=0.0123). Additionally, AA genotype carriers had significantly higher HCC risk than GG genotype carriers among males (p=0.0145) and non-alcohol drinkers (p<0.001).Conclusion: HCC risk is influenced by ALDH2 genotype, with effects modified by sex and alcohol consumption. Particularly, individuals with the ALDH2 rs671 AA genotype should avoid alcohol consumption, especially males.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Mayo Adhesive Probability Score as a Predictor of Postoperative Renal Function in Robot-assisted Partial Nephrectomy. 梅奥粘连概率评分作为机器人辅助肾部分切除术术后肾功能的预测指标。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10377

Hiroshi Matsuzaki, Kazuna Tsubouchi, Y U Okabe, Takeshi Miyazaki, Naotaka Gunge, Kosuke Tominaga, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuyuki Nakamura, Nobuhiro Haga

{"title":"The Mayo Adhesive Probability Score as a Predictor of Postoperative Renal Function in Robot-assisted Partial Nephrectomy.","authors":"Hiroshi Matsuzaki, Kazuna Tsubouchi, Y U Okabe, Takeshi Miyazaki, Naotaka Gunge, Kosuke Tominaga, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuyuki Nakamura, Nobuhiro Haga","doi":"10.21873/cdp.10377","DOIUrl":"https://doi.org/10.21873/cdp.10377","url":null,"abstract":"Background/aim: The aim of this study was to evaluate the Mayo Adhesive Probability (MAP) score as a predictor of split renal function deterioration after robot-assisted partial nephrectomy (RAPN).Patients and methods: A total of 30 patients who underwent RAPN were identified retrospectively. The parameters evaluated included patient characteristics, tumor diameter, MAP score, warm ischemic time (WIT), and renal function. Split renal function was evaluated using Tc-99m DTPA renal scintigraphy before and six months after surgery. Univariate and multivariate logistic regression analyses were performed.Results: Nine patients (30.0%) showed more than 90% preservation of split renal function on the operated side. The MAP score (p=0.015), cT1b tumor (p=0.0002), and WIT (p=0.044) were associated with preservation of split renal function six months after surgery on univariate analysis. The MAP score was the strongest predictor of preservation of split renal function six months after surgery on multivariable analysis (p=0.007). On receiver-operating characteristic (ROC) curve analysis, the MAP score (cutoff value 3.0; p=0.01) was a significant predictor of split renal function six months after surgery.Conclusion: The MAP score was significantly associated with postoperative split renal function six months after RAPN on the operated kidney side. The MAP score is useful for predicting split renal function after RAPN.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer. Oncotype-DX HER2 单基因评分与免疫组化评估 HER2 低表达乳腺癌中 HER2 表达的关系

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10370

George Douganiotis, Loukas Kontovinis, Thomas Zarampoukas, Ioannis Natsiopoulos, Konstantinos Papazisis

{"title":"Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer.","authors":"George Douganiotis, Loukas Kontovinis, Thomas Zarampoukas, Ioannis Natsiopoulos, Konstantinos Papazisis","doi":"10.21873/cdp.10370","DOIUrl":"https://doi.org/10.21873/cdp.10370","url":null,"abstract":"Background/aim: \"HER2-low\" is an emerging subtype of breast cancer, with a documented role in predicting response to treatment with novel antibody-drug conjugates. It is defined based on immunohistochemistry, but increasing evidence is challenging this approach as appropriate for identifying the HER2-low subgroup, due to both interobserver variability and limitations of the method itself.Patients and methods: We retrospectively analyzed data from 430 patients from our departmental databases who had been subjected to an Oncotype-DX score and assessed the correlation of the Oncotype-DX HER2 single-gene score with the HER2 expression on immunohistochemistry. The Oncotype-DX Recurrence Score was also evaluated in the HER2-0 versus HER2-low subgroups.Results: The HER2 single-gene score was found to accurately correlate with the HER2 result on immunohistochemistry, with a statistically significant difference both between HER2-0 and HER2 +1 tumors (p<0.0001), as well as between HER2 +1 and +2 tumors (p<0.0001). There was no statistically significant difference in the recurrence score between the HER2-0 and the HER2-low subgroups.Conclusion: Oncotype-DX single-gene scores for HER2 are a potential surrogate marker for assessing the precise HER2 status, with better reproducibility and less interobserver variance compared to immunohistochemistry. The use of rt-PCR emerges as an alternative method of assessment of the HER2-low subgroup.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0